New treatment approach for chronic neuropathic pain
Immunomodulatory Therapy for Neuropathic Pain
This study is testing a new treatment using a low dose of a substance called interleukin-2 to help people with neuropathic pain feel better by boosting their body's natural defenses, and if you join, you could help us learn how well it works!
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Apt Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Naperville, UNITED STATES) |
| Project ID | NIH-10684821 on NIH RePORTER |
What this research studies
This research investigates a novel immunomodulatory therapy aimed at treating neuropathic pain, which affects millions of Americans. The approach focuses on using low-dose interleukin-2 (IL-2) to enhance the body's regulatory T cells, which may help reduce inflammation and improve pain management. By targeting the underlying mechanisms of neuropathic pain rather than just alleviating symptoms, this therapy seeks to provide a more effective and safer alternative to current opioid treatments. Patients participating in this research may receive this innovative therapy and contribute to understanding its effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic neuropathic pain who have not found relief from existing treatments.
Not a fit: Patients with acute pain conditions or those who do not have neuropathic pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer, non-opioid treatment option for patients suffering from chronic neuropathic pain.
How similar studies have performed: Previous studies have shown promising results with similar immunomodulatory approaches in treating autoimmune diseases, suggesting potential for success in neuropathic pain management.
Where this research is happening
Naperville, UNITED STATES
- Apt Therapeutics, INC. — Naperville, United States (Active)
Researchers
- Principal investigator: Chen, Ridong — Apt Therapeutics, INC.
- Study coordinator: Chen, Ridong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.